Miodownik Chanoch, Alkatnany Awad, Frolova Katherina, Lerner Vladimir
Division of Psychiatry, Ministry of Health Mental Health Center, Faculty of Health Sciences Ben-Gurion University of the Negev, Be'er-Sheva, Israel.
Clin Neuropharmacol. 2008 May-Jun;31(3):176-9. doi: 10.1097/WNF.0b013e31814a619d.
Acute lithium intoxication is a frequent complication of this treatment used for manic depressive disorders. Because lithium has a narrow therapeutic index and widespread use, its neuropsychiatric side effects are more prevalent than those of other psychotropic medications. There are only few reports about it within therapeutic serum levels. The question of toxic interactions resulting from combinations of lithium and neuroleptic drugs is largely based on anecdotal reports.
We report here a case of a patient with schizophrenia with severe delirium developed shortly after initiation of a lithium-quetiapine combination therapy, despite therapeutic doses of both medications.
The psychiatric symptoms disappeared when lithium was stopped. We interpret these symptoms as delirium with pseudodementia at therapeutic lithium serum levels. Our conclusion is that lithium-induced neurotoxicity should be suspected in any patient receiving lithium in combination with neuroleptics or any other clinical variable. In such cases, regardless of lithium serum levels, the clinician should consider immediate discontinuation of the medication.
急性锂中毒是用于治疗躁郁症的这种疗法常见的并发症。由于锂的治疗指数狭窄且使用广泛,其神经精神副作用比其他精神药物更为普遍。关于其在治疗性血清水平范围内的报道很少。锂与抗精神病药物联合使用产生毒性相互作用的问题很大程度上基于轶事报道。
我们在此报告一例精神分裂症患者,在开始锂盐与喹硫平联合治疗后不久出现严重谵妄,尽管两种药物均为治疗剂量。
停用锂后精神症状消失。我们将这些症状解释为锂治疗性血清水平时伴有假性痴呆的谵妄。我们的结论是,任何接受锂与抗精神病药物联合治疗或存在任何其他临床变量的患者都应怀疑锂诱导的神经毒性。在这种情况下,无论锂血清水平如何,临床医生都应考虑立即停药。